SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

11118	Companies
244800	Keywords
172882	Articles
131992	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 03/04/2026 at 18:30, 6 months 29 days ago

Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report
Sanofi files amendment to French 'Document d’Enregistrement Universel' with annual financial report, including governance updates. Available on Sanofi and AMF websites

AMF Financial Report Amendment Sanofi Governance Updates
BRIEF

published on 02/27/2026 at 13:08, 7 months 4 days ago

Sanofi and Regeneron’s Dupixent Recommended for EU Approval in Treating Pediatric CSU

Sanofi Dupixent CSU Regeneron EMA Approval
PRESS RELEASE

published on 02/27/2026 at 13:03, 7 months 4 days ago

Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment. Positive CHMP opinion based on clinical studies

Sanofi Dupixent EU Approval CSU Regeneron
BRIEF

published on 02/24/2026 at 15:35, 7 months 7 days ago

Sanofi and Regeneron's Dupixent Gains FDA Approval for AFRS Treatment

FDA Approval Type 2 Inflammation Dupixent Approval Allergic Fungal Rhinosinusitis Sanofi And Regeneron
PRESS RELEASE

published on 02/24/2026 at 15:30, 7 months 7 days ago

Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Sanofi and Regeneron's Dupixent approved in the US as the first medicine for allergic fungal rhinosinusitis, supported by phase 3 study. A breakthrough in treating chronic sinus disease

Sanofi Phase 3 Study Dupixent Regeneron Allergic Fungal Rhinosinusitis
BRIEF

published on 02/17/2026 at 19:05, 7 months 13 days ago

Sanofi publishes its 2025 Universal Registration Document

Sustainability Financial Report Sanofi Registration Document DRY
BRIEF

published on 02/17/2026 at 12:05, 7 months 14 days ago

Sanofi and Teva: Promising advance in the treatment of inflammatory bowel diseases

Ulcerative Colitis Sanofi Teva Crohn's Disease Duvakitug
BRIEF

published on 02/17/2026 at 12:05, 7 months 14 days ago

Sanofi and Teva Report Positive Phase 2b Data for Duvakitug in IBD

Ulcerative Colitis Crohn’s Disease Phase 2b Study Duvakitug Sanofi-Teva Collaboration
PRESS RELEASE

published on 02/17/2026 at 12:00, 7 months 14 days ago

Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
Sanofi and Teva's duvakitug phase 2b maintenance data show durable efficacy in ulcerative colitis and Crohn's disease. Results reinforce ongoing phase 3 programs in UC and CD

Ulcerative Colitis Sanofi Teva Crohn's Disease Duvakitug
BRIEF

published on 02/16/2026 at 07:05, 7 months 15 days ago

Beyfortus proves its effectiveness beyond the first season of VRS

Sanofi VRS Beyfortus Infants Immunization

Accesswire

Published on 10/03/2026 at 02:35, 13 hours 12 minutes ago

Jaguar Health Announces a Special Stock Dividend
Published on 10/02/2026 at 17:45, 22 hours 2 minutes ago

Sparton Provides Status Update
Published on 10/02/2026 at 13:50, 1 day 1 hour ago

AI/ML Innovations Appoints Lynn Chapman as Chief Financial Officer and Announces Share Issuance for Debt Settlement
Published on 10/02/2026 at 13:00, 1 day 2 hours ago

Evergold Drills 4.9 m of 7.70 g/t Au and 186.0 g/t Ag Within 13.5 Metres of 2.84 g/t Au and 127.6 g/t Ag in First 2026 Drill Holes at Golden Lion
Published on 10/02/2026 at 13:00, 1 day 2 hours ago

Alaska Energy Metals Appoints Independent Director, Thomas Benson

View all ACCESSWIRE

EQS Group

Published on 10/02/2026 at 23:55, 15 hours 52 minutes ago

IS SKINCARE GETTING TOO COMPLICATED? CERAVE MAKES THE CASE FOR SAFETY, EFFICACY AND SIMPLICITY
Published on 10/02/2026 at 20:23, 19 hours 23 minutes ago

EQS-Adhoc: Pentixapharm Holding AG: Bafin concludes financial reporting review of the 2024 consolidated financial statements with an error finding
Published on 10/02/2026 at 19:46, 20 hours ago

innoscripta SE: Update on the Tax Authorities’ Investigation – Business Operations Continue as Usual – Full Transparency Assured – Invitation to Shareholders for an In-Person Product Presentation
Published on 10/02/2026 at 18:00, 21 hours 47 minutes ago

EQS-Adhoc: AMUNDI PHYSICAL GOLD ETC (the “ETC”): Release of the first Supplemental Base Prospectus (the “Supplemental”)
Published on 10/02/2026 at 18:00, 21 hours 47 minutes ago

AMUNDI PHYSICAL GOLD ETC (the “ETC”): Release of the first Supplemental Base Prospectus (the “Supplemental”)

Les Echos

Published on 10/02/2026 at 17:45, 22 hours 2 minutes ago

Information concerning the total number of voting rights and shares 2026 09 30
Published on 10/02/2026 at 17:30, 22 hours 17 minutes ago

Aéroports de Paris SA - 2027 Financial Calendar
Published on 10/01/2026 at 19:00, 1 day 20 hours ago

AMA CORP PLC reduces its cost base while preserving XpertEye’s key functions
Published on 10/01/2026 at 18:40, 1 day 21 hours ago

Monthly disclosure of the total number of shares and voting rights - September 2026
Published on 10/01/2026 at 18:05, 1 day 21 hours ago

Covivio - Information on total number of voting rights and share capital

View all LES ECHOS COMFI WIRE